Oncology Drugs

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

Taiwan's PharmaEssentia is building a new U.S. facility in Puerto Rico, a move set to bolster drug supply chains and deepen US-Taiwan economic ties.

With FDA clearance for clinical trials, CanWell Pharma’s novel CAN016 ADC brings a two-pronged attack against drug-resistant HER2-positive cancers.

With a new patent for its drug ALPHA-1062, Alpha Cognition may become a first-mover in the $14 billion traumatic brain injury market, which has no approved therapies.

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

A new investigation shows drug companies make $31 in profit for every $1 paid in penalties, suggesting fines are just a cost of doing business.

Veteran biotech CEO Paul Sekhri joins investor Petrichor, signaling a strategic shift where hands-on leadership is now paramount in life sciences investing.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

Nominations are open for the $100,000 Fogarty Prize, continuing the mission of the late Dr. Thomas Fogarty by celebrating life-changing medical innovations.